GlassScriptPhysician profile
Todd H Perkins
NPI 1649470097
$22,490.44
in general payments reported to CMS, 2019-2025
56 companies · $3,121 in 2025
The $3,121 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,208 · 2020: $2,198 · 2021: $4,311 · 2022: $3,370 · 2023: $3,133 · 2024: $3,149 · 2025: $3,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,403.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,606.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,585.68 | 2019-2025 | |
| Novo Nordisk INC | $2,365.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,746.15 | 2019-2025 | |
| Lilly USA, LLC | $1,288.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,251.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $1,188.43 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,027.53 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $937.94 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $811.66 | 2019-2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $507.95 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Astellas Pharma US INC | $394.73 | 2019-2024 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $393.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.77 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Lundbeck LLC | $355.99 | 2023-2025 | Rexulti, Vyepti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.